{"filings":[{"id":1065996,"accession_number":"0001628280-26-043416","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2026-06-16T11:34:21+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Acumen nominates two EBD Alzheimer's candidates (ACU301, ACU401); IND in mid-2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nominated ACU301 (bispecific from sabirnetug) and ACU401 (novel AβO-selective antibody ACU234).","Exercised option under JCR collaboration; combines Acumen's AβO antibody with J-Brain Cargo BBB-penetrating tech.","Preclinical data: 14-40x higher brain penetration in NHPs vs native antibodies; low anemia risk; no adverse events.","IND-enabling activities ongoing; IND submission targeted mid-2027; SC dosing suitability demonstrated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":835077,"accession_number":"0001628280-26-040447","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2026-06-03T20:43:17+00:00","items":["5.07"],"status":"ready","headline":"Acumen stockholders elect three Class II directors, approve equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Golumbeski (37.3M for), Porter (30.9M for), Stoppel (30.8M for) as Class II directors.","Ratified Ernst & Young as auditor for FY 2026: 56.9M for, 113k against.","Approved Amended and Restated 2021 Equity Incentive Plan: 30.7M for, 6.6M against, 19.7M broker non-votes.","Turnout: 57.1M of 72.2M shares (78.99%) present or represented at annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22285,"accession_number":"0001628280-26-033868","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2026-05-12T11:07:44+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen posts Q1 net loss $20.7M; Phase 2 AD topline results expected late 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities totaled $128.4M as of Mar 31, 2026; funded into early 2027.","Net loss $20.7M for Q1 2026 vs $28.8M in Q1 2025; R&D expense fell to $16.5M from $25.3M.","Topline results from Phase 2 ALTITUDE-AD study (sabirnetug, early Alzheimer's) due late 2026.","Option to license two candidates from JCR EBD collaboration expected in Q2 2026.","Targeting IND filing for EBD lead candidate in mid-2027."],"consensus_eps_estimate":-0.4108,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105719,"accession_number":"0001628280-26-021189","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen reports FY2025 net loss $121.3M; cash $116.9M; ALTITUDE-AD topline due late 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $121.3M for FY2025 ($102.3M in FY2024); R&D expenses rose to $104.9M.","Cash, equivalents and marketable securities $116.9M as of Dec 31, 2025; expected to fund operations into early 2027.","Phase 2 ALTITUDE-AD (sabirnetug) topline results expected late 2026; OLE dosing commenced Nov 2025.","$35.75M private placement closed March 2026 to advance Enhanced Brain Delivery (EBD) program; IND filing targeted mid-2027.","EBD program candidates showed up to 40-fold brain exposure in NHPs; low anemia risk; subcutaneous potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105718,"accession_number":"0001628280-26-017885","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Acumen raises $35.75M, reports positive EBD preclinical data with 14-40x brain penetration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $35.75M from private placement of 10,833,331 shares at $3.30/share; led by RA Capital.","Preclinical data for EBD program: 14-40x brain levels in NHPs vs. native antibodies; low anemia risk.","Subcutaneous dosing feasible; IND submission for lead candidate targeted for mid-2027.","Proceeds primarily to support EBD program preclinical work and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105717,"accession_number":"0001628280-26-001774","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acumen updates corporate presentation with new EBD data, ACU234 pipeline addition","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Nonclinical murine brain exposure data for Enhanced Brain Delivery program presented at CTAD 2025 included.","Updated fluid biomarker data from Phase 1 INTERCEPT-AD study added to presentation.","ACU234, a new candidate under the EBD program, now listed in pipeline.","Presentation posted on company website for use in conferences and communications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121993,"accession_number":"0001576885-25-000102","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen reports Q3 net loss $26.5M; cash $136.1M supports ops into early 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents & marketable securities $136.1M at Sept 30, down from $166.2M at June 30; runway into early 2027.","Net loss $26.5M vs $29.8M YoY; R&D expense fell to $22.0M from $27.2M.","First patient dosed in November 2025 in open-label extension of Phase 2 ALTITUDE-AD trial of sabirnetug.","Expect non-clinical data for EBD candidate in early 2026; Phase 2 topline results in late 2026.","Added biopharma veteran George Golumbeski as Chairman, board expanded to 8 members."],"consensus_eps_estimate":-0.6157,"consensus_eps_actual":-1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121992,"accession_number":"0001628280-25-050800","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Acumen appoints George Golumbeski as Chairman, replaces Sean Stalfort","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. George Golumbeski appointed as director and Chairman of Board, effective Nov 6, 2025.","Golumbeski received initial option to buy 50,000 shares at closing price, vesting over 3 years.","Annual retainer: $40,000 for board service plus $30,000 as Chairman.","Board now has 8 members; Golumbeski brings 30+ years biopharma experience from Celgene, Novartis.","Company highlights Phase 2 sabirnetug trial and Enhanced Brain Delivery program as key 2026 catalysts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138703,"accession_number":"0001576885-25-000091","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen reports Q2 2025 net loss $41M, cash $166.2M; Phase 2 Alzheimer's topline expected late 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities totaled $166.2M as of June 30, 2025, expected to fund operations into early 2027.","Net loss for Q2 2025 was $41.0M compared to $20.5M in Q2 2024, driven by higher R&D expenses.","Topline results from Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer's expected in late 2026.","Announced collaboration with JCR Pharmaceuticals for Enhanced Brain Delivery therapy; non-clinical data expected early 2026.","At AAIC 2025, presented data showing sabirnetug has 8,750-fold selectivity for toxic amyloid beta oligomers over monomers."],"consensus_eps_estimate":-0.5488,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138702,"accession_number":"0001576885-25-000087","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Acumen Pharma enters Alzheimer's collaboration with JCR; up to $555M in milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["JCR receives upfront payment (undisclosed) plus $9.25M option fee if Acumen exercises right to develop two candidates.","Total milestones up to $555M ($40M development, $515M sales) plus single-digit royalties on sales.","Leverages Acumen's amyloid beta oligomer antibodies and JCR's transferrin-receptor BBB technology for Alzheimer's.","Company expects preclinical data package in early 2026 to support option exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156147,"accession_number":"0001576885-25-000072","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acumen shareholders elect three Class I directors, ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Kimberlee C. Drapkin, Jeffrey Ives, and Sean Stalfort as Class I directors until 2028 with ~30M votes each; ~17.5M broker non-votes.","Ratified Ernst & Young as independent auditor for FY2025: 51.4M for, 118,735 against, 35,514 abstain.","Approximately 85% of outstanding shares (51.5M of 60.6M) were present or represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156146,"accession_number":"0001576885-25-000062","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen Pharma Q1 net loss $28.8M; Phase 2 Alzheimer's trial fully enrolled, results late 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $28.8M in Q1 2025 ($14.9M Q1 2024); loss from operations $30.4M vs $17.8M.","R&D expenses $25.3M (up 104% YoY) driven by ALTITUDE-AD Phase 2 clinical trial costs.","Cash, cash equivalents and marketable securities $197.9M, expected to fund operations into early 2027.","Phase 2 ALTITUDE-AD study of sabirnetug fully enrolled (542 participants); topline data readout late 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174591,"accession_number":"0001576885-25-000044","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen 2024 net loss $102.3M; cash $231.5M; ALTITUDE-AD enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $102.3M vs $52.4M in 2023; R&D spend $93.8M (up 122%) driven by ALTITUDE-AD trial.","Cash, equivalents and marketable securities $231.5M, down from $306.1M; runway into H1 2027.","Phase 2 ALTITUDE-AD enrolled 542 early AD patients; topline results expected late 2026.","Phase 1 subcutaneous sabirnetug showed mild injection-site reactions; supports further SC development.","JPAD published Phase 1 INTERCEPT-AD results; sabirnetug well-tolerated with dose-dependent target engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191555,"accession_number":"0001576885-24-000096","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen Q3 net loss $29.8M; cash $258.9M; ALTITUDE-AD enrollment on track for H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $29.8M for Q3 2024 vs $13.0M in Q3 2023, driven by higher R&D costs ($27.2M vs $11.2M).","Cash, equivalents and marketable securities of $258.9M as of Sept 30, 2024, expected to fund operations into H1 2027.","Phase 2 ALTITUDE-AD enrollment for sabirnetug expected to complete in first half of 2025.","Topline results from Phase 1 subcutaneous sabirnetug study anticipated in Q1 2025.","Appointed Amy Schacterle, PhD as Chief Regulatory Officer & Head of Quality in November 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208028,"accession_number":"0001576885-24-000090","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen Q2 net loss expands to $20.5M; Phase 2 AD trial enrollment ahead of expectations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.5M in Q2 2024 vs $11.6M in Q2 2023; R&D spending rose to $19.5M (from $9.1M) on ALTITUDE-AD costs.","Cash, equivalents, and securities $281.4M at June 30, 2024 (down from $306.1M at Dec 31, 2023); runway into H1 2027.","Phase 2 ALTITUDE-AD enrollment faster than expected; over 50 sites activated in U.S., Canada, U.K., EU.","Phase 1 subcutaneous sabirnetug study dosed first subject July 2024; topline data expected Q1 2025.","Virtual R&D Day planned Oct 2, 2024, to detail sabirnetug science and Phase 1 results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225565,"accession_number":"0001576885-24-000067","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acumen stockholders elect two Class III directors, ratify Ernst & Young as auditor for FY2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Daniel O'Connell received 40,490,834 votes for, 48,338 withheld; Nathan Fountain 34,164,444 for, 6,371,549 withheld.","Ratification of Ernst & Young as auditor: 52,367,645 for, 7,093 against, 6,271 abstained.","Approximately 87% of outstanding shares (52,381,009 of 60,079,778) were present at the annual meeting.","Directors elected to serve until the 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225564,"accession_number":"0001576885-24-000061","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen reports Q1 net loss of $14.9M; Phase 2 sabirnetug trial initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.9M for Q1 2024 vs. $11.3M in Q1 2023; R&D expenses rose to $12.4M.","Cash, equivalents and marketable securities totaled $296.6M as of March 31, 2024; expected to fund operations into H1 2027.","First patient dosed in ALTITUDE-AD Phase 2 study of sabirnetug for early Alzheimer's in May 2024.","Phase 1 subcutaneous dosing study of sabirnetug expected to start mid-2024; Lonza collaboration for manufacturing announced."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244730,"accession_number":"0001576885-24-000044","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acumen Pharma FY2023 net loss $52.4M; cash $306.1M; Phase 2 AD trial to start H1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $52.4M in FY2023 vs $42.9M in 2022; operating loss $61.1M.","Cash, equivalents and marketable securities $306.1M, sufficient for operations into H1 2027.","R&D expenses $42.3M (up $9.9M); G&A $18.8M (up $5.9M).","Plan to initiate Phase 2 ALTITUDE-AD trial of sabirnetug in early AD patients in H1 2024, plus subcutaneous PK study mid-2024.","Appointed Dr. James Doherty as President and Chief Development Officer in Feb 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244729,"accession_number":"0001576885-24-000039","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen reports $306M cash, runway into H1 2027; plans Phase 2-only ALTITUDE-AD study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities ~$306M as of Dec 31, 2023 (preliminary, unaudited).","Company expects cash to fund operations into first half of 2027.","Anticipates amending ALTITUDE-AD Phase 2/3 protocol to a standalone Phase 2 study.","Updated corporate presentation posted on investor website on March 19, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244728,"accession_number":"0001576885-24-000032","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Acumen appoints Dr. James Doherty as President and Chief Development Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. James Doherty appointed President and Chief Development Officer effective Feb 1, 2024, reporting to CEO Daniel O'Connell.","Doherty previously served as Chief Development Officer at Sage Therapeutics, contributing to two FDA approvals for postpartum depression.","He will oversee clinical/non-clinical development, CMC, and regulatory functions as Acumen prepares to initiate ALTITUDE-AD study for ACU193.","Daniel O'Connell's title changes to CEO (previously CEO and President) as Doherty assumes the President role.","Doherty led Alzheimer's research at AstraZeneca and holds a Ph.D. in Neurobiology from Georgetown University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244727,"accession_number":"0001576885-24-000018","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2024-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acumen Pharmaceuticals posts updated corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01; presentation posted to company website on January 12, 2024.","Presentation covers corporate overview and strategy but no specific financial or clinical updates in the excerpt provided.","No new earnings, guidance, trial results, or other material events referenced in the filing or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244726,"accession_number":"0001576885-24-000015","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acumen posts updated corporate presentation with additional ACU193 biomarker data at J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company posted updated corporate presentation on its website with additional biomarker data for ACU193.","Presentation used at J.P. Morgan Healthcare Conference on January 8, 2024.","No specific financial results or guidance changes disclosed.","ACU193 is an investigational drug for Alzheimer's disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262170,"accession_number":"0001576885-23-000068","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acumen posts updated corporate presentation with plasma biomarker data from Phase 1 INTERCEPT-AD trial","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Updated corporate presentation posted to investor website on December 4, 2023.","Includes plasma biomarker data from Phase 1 INTERCEPT-AD trial.","Presentation to be used in upcoming investor conferences and communications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262169,"accession_number":"0001576885-23-000065","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acumen updates ACU193 Phase 1 subcutaneous trial to mid-2024; secures $50M credit facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Projected mid-2024 initiation of Phase 1 subcutaneous trial for ACU193.","Reported results from recent FDA interaction regarding ACU193 development.","Additional CSF biomarker data from Phase 1 INTERCEPT-AD trial presented.","New credit facility of up to $50 million from K2 HealthVentures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262168,"accession_number":"0001576885-23-000058","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen reports Q3 net loss $13M, plans Phase 2 AD trial H1 2024, secures $50M credit facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2 ALTITUDE-AD trial expected to initiate H1 2024 after positive FDA feedback on study design.","CSF biomarkers p-tau181 (p=0.049) and neurogranin (p=0.037) significantly improved at 60 mg/kg dose in Phase 1.","Credit facility up to $50M from K2 HealthVentures; $30M drawn at closing, matures Nov 2027 or 2028 upon milestones.","Cash and equivalents $282.7M as of Sept 30, 2023; expected to fund operations into H2 2026.","Net loss $13.0M for Q3 2023 vs $10.7M Q3 2022; R&D spend $11.2M vs $8.3M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262167,"accession_number":"0001576885-23-000056","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Acumen licenses Halozyme ENHANZE tech for subcutaneous ACU193; seven-figure upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment in the seven-figure range for non-exclusive license to Halozyme's ENHANZE drug delivery technology.","Milestone payments tied to development/commercialization and net sales levels; single-digit royalties on worldwide net sales.","Halozyme named exclusive supplier of API for PH20 product for clinical and commercial supplies.","Agreement covers development of a subcutaneous formulation of ACU193."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279379,"accession_number":"0001576885-23-000047","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen reports positive Phase 1 results for ACU193; Q2 net loss $11.6M, cash $172.2M + $122M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 1 INTERCEPT-AD trial met primary/secondary objectives; ACU193 showed 25% amyloid plaque reduction at 60 mg/kg (p=0.01).","ACU193 demonstrated near-maximal target engagement of toxic AβOs; low ARIA-E rate of 10.4%, symptomatic 2.1%; no drug-related SAEs.","Cash, equivalents & securities $172.2M at June 30; July follow-on offering added ~$122M net; runway into H2 2026.","Phase 2 study initiation expected H1 2024; FDA interaction anticipated Q4 2023 to inform development path.","Q2 2023 net loss $11.6M vs $10.2M YoY; R&D expenses $9.1M (up from $7.3M); no revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279378,"accession_number":"0001193125-23-190489","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Acumen Pharmaceuticals prices public offering of 16.8M shares at $7.75/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 16,774,193 shares at $7.75 each; underwriters have 30-day option for up to 2,516,128 additional shares.","Underwriters include BofA Securities, Citigroup Global Markets, and Stifel; closing expected July 21, 2023.","Estimated offering expenses of ~$440,000 excluding underwriting discounts; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279377,"accession_number":"0001193125-23-188158","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Acumen Pharmaceuticals files preliminary prospectus for common stock offering; reports $172.2M cash as of June 30, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company plans to offer shares of common stock; no terms disclosed.","Preliminary cash and cash equivalents and marketable securities total $172.2M as of June 30, 2023.","Financial results for Q2 2023 are preliminary and subject to completion; actual results may differ materially."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279376,"accession_number":"0001193125-23-187579","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Acumen's ACU193 Phase 1 meets endpoints; plaque reduction up to 25%, low ARIA-E rate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["60 mg/kg Q4W cohort showed 25% mean amyloid plaque reduction at day 63; 25 mg/kg Q2W showed 20% at day 70.","Overall ARIA-E rate 10.4% (5/48); symptomatic ARIA-E 2.1% (1/48); no drug-related serious adverse events.","Statistically significant dose-proportional PK and near-maximal target engagement of toxic AβOs in CSF.","Monthly dosing supported by pharmacokinetic and CSF data; company plans FDA interaction in Q4 2023.","INTERCEPT-AD enrolled 60 early-AD participants; results to be submitted for peer-reviewed publication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.88,"calibrated_materiality_score":0.88,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297752,"accession_number":"0001576885-23-000039","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Acumen shareholders approve officer exculpation amendment; re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved certificate amendment to allow officer exculpation per Delaware law (27,061,448 votes for, 99.9% of votes cast).","Re-elected Dr. Derrell Porter (27,096,949 for) and Dr. Laura Stoppel (24,440,807 for) as Class II directors until 2026.","Ratified Ernst & Young as independent auditor for FY2023 with 36,099,071 votes for, 185 against, 214 abstained.","Quorum of 36,099,470 shares (87.99% of 41,025,062 outstanding) present at annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297751,"accession_number":"0001576885-23-000023","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen Q1 net loss $11.3M; cash $183.8M; Phase 1 ACU193 topline due Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.3M for Q1 2023 vs $9.1M in Q1 2022; no revenue reported.","Cash, equivalents and marketable securities $183.8M as of March 31, 2023, down from $193.4M at Dec 31, 2022.","R&D expenses $8.7M (up from $6.0M) driven by ongoing Phase 1 INTERCEPT-AD trial of ACU193.","Company expects to report topline Phase 1 data for ACU193 in early Alzheimer's in Q3 2023, with FDA interaction in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297750,"accession_number":"0001193125-23-120000","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Acumen adds BTIG as ATM sales agent; $4.25M of $50M capacity used as of April 26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Added BTIG, LLC as a sales agent under the existing at-the-market (ATM) offering agreement.","Amendment to Sales Agreement dated July 1, 2022; prospectus remains for up to $50M in common stock.","As of April 26, 2023, sold 422,160 shares for aggregate proceeds of approx. $4.25M.","Shares offered through BofA Securities, Stifel, and now BTIG as sales agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318016,"accession_number":"0001576885-23-000013","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen reports FY2022 net loss $42.9M; Phase 1 ACU193 enrollment completed, topline Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $193.4M as of Dec 31, 2022, expected to fund operations through 2025.","Net loss of $42.9M for FY2022 vs $100.6M in 2021 (which included $81.2M non-cash charge).","Phase 1 INTERCEPT-AD trial of ACU193 in early Alzheimer's completed enrollment Feb 2023; topline data expected Q3 2023.","Protocol amendment reduced cohort 7 dose to 25 mg/kg Q2W after blinded PK/SA, 2 asymptomatic ARIA-E cases noted.","FDA granted Fast Track designation for ACU193 in Oct 2022; Derrell Porter, M.D. joined board in Jan 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318015,"accession_number":"0001576885-23-000008","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Acumen amends bylaws to adopt universal proxy rules and DGCL updates","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted amended bylaws effective March 9, 2023, to comply with SEC Rule 14a-19 (universal proxy) and recent DGCL changes.","Enhanced disclosure requirements for stockholder director nominations, including background info and proxy solicitation intent.","Company will disregard nominations if stockholder fails to comply with Rule 14a-19 after providing notice.","Stockholders soliciting proxies must use a proxy card other than white; white card reserved for Board use.","Updated provisions on meeting adjournment procedures and stockholder list to reflect DGCL amendments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318014,"accession_number":"0001193125-23-021525","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-02-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Acumen updates INTERCEPT-AD trial enrollment, dose reduction for Cohort 7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects enrollment completion Q1 2023, topline data Q3 2023.","52 subjects randomized and dosed in Cohorts 1-6 as of Jan 31, 2023.","Submitted protocol amendment Jan 30, 2023: Cohort 7 reduced to 25 mg/kg every 2 weeks from 60 mg/kg.","Two asymptomatic ARIA-E cases: one in Cohort 4 (single 60 mg/kg), one in Cohort 5 (third 10 mg/kg).","Dose reduction based on blinded PK/PD data; 60 mg/kg every 2 weeks deemed unnecessary for target engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318013,"accession_number":"0001193125-23-001236","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Acumen appoints Dr. Derrell Porter to board effective Jan. 4, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Porter appointed as Class II independent director; named to Nominating and Governance Committee.","He receives 50,000-share stock option with 10-yr term, vesting monthly over 3 years.","Annual retainer of $35,000 for board service and $4,000 for committee service.","Dr. Porter is Founder/CEO of Cellevolve; brings drug development and commercialization expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336272,"accession_number":"0001193125-22-284564","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acumen Q3 net loss $10.7M; INTERCEPT-AD Phase 1 on track, FDA Fast Track granted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents & marketable securities $200.2M at Sep 30, 2022, sufficient through 2025.","R&D expenses $8.3M (Q3 2022) vs $1.8M (Q3 2021) due to clinical trial ramp.","INTERCEPT-AD enrollment expected to complete Q1 2023; topline data anticipated H2 2023.","FDA granted Fast Track designation for ACU193 in early Alzheimer's in October 2022.","Appointed Derek Meisner as Chief Legal Officer in September 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336271,"accession_number":"0001193125-22-267185","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2022-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Acumen's ACU193 receives FDA Fast Track designation for early Alzheimer's disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ACU193 is first clinical-stage monoclonal antibody selectively targeting toxic soluble amyloid beta oligomers (AßOs).","Phase 1 INTERCEPT-AD trial ongoing to assess safety and proof of mechanism.","Fast Track facilitates more frequent FDA engagement to expedite development and review.","ACU193's unique binding profile may offer low risk of ARIA by avoiding direct plaque targeting.","CEO Daniel O'Connell cites potential clinical utility and collaboration with FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353686,"accession_number":"0001193125-22-242461","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2022-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acumen posts updated corporate presentation on website; no new material data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted updated corporate presentation dated September 2022 to its investor website on September 12, 2022.","Presentation may be used in communications or conferences; filing under Regulation FD.","No specific financial, clinical, or operational updates provided in the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353685,"accession_number":"0001193125-22-221242","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Acumen Q2 net loss $10.2M; cash $209.9M; Phase 1 topline H1 2023; director resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $209.9M as of June 30, 2022; expected runway through 2025.","Net loss $10.2M for Q2 2022 vs $61.4M in Q2 2021 (2021 incl $57.9M non-cash liability charge).","R&D expenses $7.3M (up from $2.3M) due to ongoing Phase 1 INTERCEPT-AD trial.","Phase 1 INTERCEPT-AD topline results expected H1 2023; 15 active sites recruiting.","Dr. Jeffrey Sevigny resigned from Board effective Aug 12, 2022 due to employment requirements, not disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353684,"accession_number":"0001193125-22-208858","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acumen presents ADDL assay method to standardize AßO testing for Alzheimer's therapeutics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Presented poster at AAIC 2022 on using ADDLs as synthetic AßO reference standard for bioanalytical assays.","ADDL model addresses low concentration, instability, and heterogeneity of sAßOs in Alzheimer's brain.","ACU193 Phase 1 trial ongoing; poster supports understanding of oligomer role in Alzheimer's disease.","Panel of sAßO-targeting antibodies showed variable immunoreactivity with ADDLs; 20C2 selective over monomers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371479,"accession_number":"0001193125-22-177636","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acumen shareholders elect all director nominees and ratify E&Y as auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class I director nominees elected: Kimberlee C. Drapkin, Jeffrey Ives (Ph.D.), Sean Stalfort; broker non-votes of 5,658,008.","Ratification of Ernst & Young as independent auditor received 34,702,393.73 votes for, 761.18 against, 165 abstentions.","Approximately 85.69% of outstanding shares (34,703,319.92 of 40,496,512) were present or represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371478,"accession_number":"0001193125-22-151761","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acumen Q1 2022 net loss $9.1M; cash $216.7M, runway through 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities totaled $216.7M as of March 31, 2022, down from $225.9M at year-end 2021; expected to fund operations through 2025.","R&D expenses rose to $6.0M from $2.6M YoY due to ongoing Phase 1 trial (INTERCEPT-AD) of ACU193 for early Alzheimer's.","Net loss was $9.1M vs $27.0M in Q1 2021; prior-year loss included $23.2M non-cash expense from warrant/liability fair value changes.","Topline data from INTERCEPT-AD Phase 1 trial expected in first half of 2023; enrollment ongoing.","Preclinical evidence supporting ACU193's selective targeting of soluble amyloid-beta oligomers published in Frontiers in Neuroscience."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390442,"accession_number":"0001193125-22-086678","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2022-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acumen reports FY2021 net loss $100.6M; Phase 1 ACU193 topline results expected H1 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $225.9M at Dec 31, 2021; provides runway through 2025.","Net loss $100.6M for FY2021 includes $81.2M non-cash fair value adjustment; operating loss $19.6M.","R&D expenses $12.3M (up from $8.0M) driven by clinical trial initiation; G&A $7.3M (up from $1.4M).","Topline results from INTERCEPT-AD Phase 1 trial of ACU193 now expected first half of 2023 due to slower enrollment from COVID-19.","Kim Drapkin appointed to Board of Directors effective Apr 1, 2022; three new team members added in Q4 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390441,"accession_number":"0001193125-22-000603","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2022-01-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Acumen Pharmaceuticals amends executive employment agreements with new base salaries and severance terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO O'Connell: $551,200 base salary; 55% bonus target; 12-month non-CIC severance, 18-month CIC severance.","CFO Zuga: $415,300 base; 40% bonus target; 9-month non-CIC severance, 12-month CIC severance with 1.0x bonus lump sum.","CMO Siemers ($342,000 base) and COO Barton ($299,040 base) receive same severance structure as CFO.","CIC severance includes full acceleration of time-based equity awards in addition to cash severance and COBRA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408467,"accession_number":"0001193125-21-329003","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acumen Q3 loss $3.9M, cash $229.9M; ACU193 Phase 1 trial enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.9M (Q3), $92.3M (9M) including $80.3M non-cash fair-value charges from preferred stock and warrant liabilities.","Cash and marketable securities $229.9M at Sep 30, 2021 (vs. $43.8M at Dec 2020); IPO net proceeds $168.6M in July 2021.","R&D expenses $1.8M (Q3), G&A $2.1M; loss from operations $3.9M.","INTERCEPT-AD Phase 1 trial of ACU193 (anti-AβO antibody) dosed first patient; sentinel safety review passed.","Topline data expected by end of 2022; COVID-19 Delta variant delayed site activation but recruitment ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408466,"accession_number":"0001193125-21-325299","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acumen posts presentation on ACU193 Phase 1 trial design for early Alzheimer's disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ACU193 is a monoclonal antibody that selectively targets toxic amyloid-beta oligomers for early Alzheimer's disease.","The Phase 1 INTERCEPT-AD trial design is detailed in the presentation posted on November 10, 2021.","The presentation is available on Acumen's website and was furnished to the SEC as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408465,"accession_number":"0001193125-21-293760","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2021-10-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acumen doses first patient in Phase 1 trial of ACU193 for early Alzheimer's","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in INTERCEPT-AD Phase 1 trial of ACU193 for early Alzheimer's disease.","ACU193 is the first monoclonal antibody selectively targeting toxic amyloid-beta oligomers (AβOs).","Trial is placebo-controlled, single- and multiple-dose; enrollment ongoing.","CEO Daniel O'Connell: ACU193 has distinct potential to address unmet needs in Alzheimer's."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427425,"accession_number":"0001193125-21-262161","cik":1576885,"company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","form_type":"8-K","filed_at":"2021-08-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acumen posts updated corporate presentation; no specific financial data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation posted to investor website on August 31, 2021.","Presentation may be used in upcoming investor communications and conferences.","No quarterly results, guidance, or material business developments were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":185263732.39960632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-31T23:59:59+00:00|427425"}